PIGMENTED VILLONODULAR SYNOVITIS
Clinical trials for PIGMENTED VILLONODULAR SYNOVITIS explained in plain language.
Never miss a new study
Get alerted when new PIGMENTED VILLONODULAR SYNOVITIS trials appear
Sign up with your email to follow new studies for PIGMENTED VILLONODULAR SYNOVITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill could shrink rare joint tumors without surgery
Disease control OngoingThis study tests an experimental drug called vimseltinib for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous growth in the joints that causes pain and stiffness. The trial includes 123 adults whose tumors cannot be removed by surgery. Participants receive …
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 26, 2026 09:54 UTC
-
Hope for rare joint tumor: new drug shows promise in Late-Stage trial
Disease control OngoingThis study tests a new drug called Pimicotinib (ABSK021) for people with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous tumor that grows in joints and tendons. About 94 adults with tumors that cannot be removed by surgery will receive either the drug or a placebo for…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated May 26, 2026 08:35 UTC
-
New drug shows promise for rare joint tumor – but not a cure
Disease control OngoingThis study tests an experimental drug called vimseltinib in people with a rare joint tumor (TGCT) or advanced solid tumors. The goal is to find the safest dose and see if it shrinks tumors or improves symptoms. About 120 adults will take part. This is not a cure – the drug aims t…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated May 22, 2026 14:04 UTC